The particulars: oral semaglutide · three weeks · minus 80 °C.
I am at the decision point and I would rather think it through than improvise.
I would rather spend money on measurement than on redundancy.
What is the minimum version of this that is still defensible?
three weeks is 21 days. minus 80 °C is 85 kelvin below a refrigerator, and below the glass transition of a lyophilised cake the ten-degree rule of thumb stops applying at all — solid-state chemistry is not slow liquid chemistry, it is a different regime, and the failure modes that survive it are mechanical rather than chemical. Compare that against what the certificate covers, which is the material as it left the laboratory on the date of analysis and nothing after it. That is short enough that a re-test is a stability study rather than a safety check — worth doing if you will publish the result, hard to justify if you will only reassure yourself. If you do re-test, send it for content as well as purity; the 21 days will have moved one of them further than the other.
The practical consequence is that spot-testing one vial from a new supplier is better than assuming they are all the same.
Stratified sampling — testing one vial from the top, one from the middle, and one from the bottom of a shipment — is cheap insurance against segregation.
A statement that "lot 20260412 complies with specifications" is meaningless without stating which vials from the lot were tested and how many there were.
Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.
The practical summary: a lot number without a sampling statement is a lot number without meaning.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsThe relevant detail is that the failure mode here is publishing a result that applies to the tested vial alone while implying it applies to the entire lot.
The statistical foundation here is well-established, which is why sampling plans from decades ago are still valid.
It helps to be literal here: if you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.
Assume segregation is possible, and design your sampling to catch it if it exists.
Sampling plans exist precisely because testing everything is expensive, and they define the statistical relationship between sample size and lot-wide inference.
If the entire lot failed qualification, a retest on a different vial is sometimes done, but reporting a retest result under the same lot number is misleading.
Under AQL sampling plans, testing two vials from a fifty-vial lot gives you an operating characteristic curve that tells you what risks you are accepting.
Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.
If testing multiple vials, state how many you tested and why you chose those vials.
edited 21 Sept 2024 by a_lindgren — removed a claim I could not source
The part that matters: most suppliers test one vial per lot and report the result as lot homogeneity, which is sampling one item from one lot and extrapolating wildly.
Testing a vial that has been open in the lab for three months is testing aged material, not the fresh lot, and the result should be explicitly noted as a retest.
Worth noting that thermal excursions during shipping affect different vials differently, so the lot may not be homogeneous even if it left the factory that way.
If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.